對通用電氣的中國業(yè)務(wù)來說，2015年是一段平談無奇的時光。在中國GDP增速達到官方宣布的6.9%的情況下，GE中國的銷售額僅略有上升，而GE為前者制定的增長目標每年都是兩位數(shù)。

然而，影響GE的并非中國經(jīng)濟放緩，其低迷表現(xiàn)另有原因。

中國政府持續(xù)兩年的反腐行動讓GE的本地客戶變得緊張兮兮，他們都不敢參與大型項目，因為監(jiān)管部門對這些項目審查甚嚴。GE的另一部分客戶，也就是石油和醫(yī)療保健行業(yè)的國企則正在進行重大改革和調(diào)整，這讓大宗采購很難通過審批。

不過，反腐的影響正在減弱。也許正是出于這個原因，赴香港參加《財富》最具影響力女性國際峰會的GE中國首席執(zhí)行官段小纓在接受我們采訪時表示：“可以預(yù)見，2016年中國的情況會變好。”

GE中國的年收入規(guī)模為80億美元，段小纓從2014年起擔任CEO。她說，反腐總的來說對中國有利，但“確實也讓項目決策出現(xiàn)了延誤。”這一點很重要，因為“我們的客戶大多都是國企”，是政府監(jiān)察的重點。

段小纓表示，在中國政府定于3月份頒布的“十三五”規(guī)劃中，綠色能源是一大主題。中國的用電量占全世界的三分之一。這就帶來了一個問題，因為中國70%的電力都來自燃煤發(fā)電企業(yè)。

“中國將全面轉(zhuǎn)向清潔能源，也就是天然氣、可再生能源，同時也包括更環(huán)保地使用煤炭。”段小纓預(yù)計，可再生能源和天然氣消費量將在今后五年內(nèi)翻番，而GE的業(yè)務(wù)就包括風電、水電和天然氣。

成為GE中國掌門人之前，段小纓的職務(wù)是GE醫(yī)療集團大中華區(qū)總裁。她說，在GE的所有中國業(yè)務(wù)中，醫(yī)療部門的前景也許最為光明，甚至超過了航空業(yè)務(wù)；而后者制造飛機發(fā)動機的速度幾乎無法跟上中國交通運輸需求的增長。

在今年早些時候的業(yè)績發(fā)布會上，GE首席執(zhí)行官杰夫?伊梅爾特曾表示，GE的醫(yī)療設(shè)備業(yè)務(wù)度過了“艱難時期”的第二個年頭。

在中國，公立醫(yī)院人滿為患。患者可能要花幾個小時來排隊掛號，還要經(jīng)歷漫長的等待，才能獲得短時間的診治。為解決這個令人頭疼的問題，中國政府在最近的改革中將發(fā)展民營醫(yī)院作為一條出路。

民營醫(yī)院買得起GE銷售的昂貴醫(yī)療設(shè)備，比如CT掃描儀，原因是它們診治的是中國的富裕階層。對于其他民眾，中國政府正在推廣基本醫(yī)療設(shè)施。這些設(shè)施在美國很普通，在中國卻很少見。

“在中國，GE銷售的所有大型設(shè)備都要通過公開招標，而反腐打斷了招標活動。這和民營領(lǐng)域不同，在民營領(lǐng)域是純粹的商業(yè)談判。”段小纓如此分析。

不過，去年采購的放緩創(chuàng)造了大量需求，而且段小纓認為這些需求將在今年顯現(xiàn)出來。她說：“觀察一下就會發(fā)現(xiàn)，購買意愿非常強烈。”

這可能不是樂觀，這也許只是一家和中國國企關(guān)系密切、但在兩年的大規(guī)模反腐中頗為受傷的跨國公司看到的現(xiàn)狀。（財富中文網(wǎng)）

譯者：Charlie

審校：詹妮

Last year was forgettable for GEin China. Sales grew only slightly in a market that officially registered 6.9% GDP growth and was one in which GE set goals for double-digit growth year in and year out.

But it wasn’t China’s slowing economy that hurt GE. The weak performance had a couple of other causes.

The government’s continuing two-year anti-corruption campaign turned GE’s local customers into nail-biting bureaucrats afraid to engage in big projects that were getting scrutinized by regulators. It was also GE’s customers themselves, the government-owned companies (SOEs) in oil and health care who are undergoing heavy reforms and changes that make big purchases hard to approve.

The thawing of that campaign may be why Rachel Duan, CEO of GE China, told Fortune in an interview after her appearance at Fortune Most Powerful Women International Summit in Hong Kong today, “We can expect 2016 to be a good year in China.”

Duan, who has led GE’s $8 billion revenue China business since 2014, said the anti-corruption campaign is generally a good thing for China, but “it does impact the project decision delays.” And that matters because “most of our customers are SOEs” who face the most government scrutiny.

Duan said green energy is a big theme of the government’s new five-year plan, to be released in March. One third of electricity usage in the world is in China. That’s problematic considering 70% of China’s electricity is derived from coal. “There’s going to be a tremendous shift toward clean energy—that’s [natural] gas, that’s renewables, but also more clean-based coal use,” she says. Duan expects renewables and natural gas use to double in the next five years. GE has businesses in wind, hydro power and natural gas.

Before Duan took over GE’s China business, she ran its health care division in the country. She says that division might have the brightest prospects out of any for GE in China, including aviation, which almost can’t build jet engines fast enough to keep up with travel demand in the country.

GE’s medical equipment division last year posted what GE CEO Jeff Immelt said during an earnings release earlier this year was the second of “a tough couple of years.”

But recent government reforms have promoted private hospitals as a solution for China’s nagging issue of overcrowded public hospitals, where patients often line up at three or four in the morning to wait all day for a brief consultation with a doctor.

The private hospitals can afford the expensive medical equipment GE sells, like CT scanners, because the richest in China are visiting them. For everyone else, the government is beginning to push primary care facilities, which are normal in the U.S. but almost nonexistent in China.

“In China every large piece of equipment we sell in the space is going through a public tender. The tendering process has been interrupted by the anti-corruption campaign,” Duan says. “It’s not like private sector [where] it’s purely a business negotiation.”

However, the slowdown in buying last year has created a well of demand, which Duan says will become apparent this year. “When you look at intent to buy, it’s very robust,” she says.

It may not be optimism, it may just be the reality of what a multinational with close ties to government customers sees in China today following a huge and often debilitating two-year anti-corruption campaign.